Nuclear transcription factor-κB as a target for cancer drug development

Leukemia

Volumn 16, Issue 6, 2002, Pages 1053-1068

  Garg, A ^a   Aggarwal, B B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Cancer; Drug development; Inflammation; I B kinase (IKK); Nuclear factor kappa B (NF B)

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; CADMIUM; CAPSAICIN; CHROMIUM; CURCUMIN; CYCLOSPORIN A; DEXAMETHASONE; DISULFIRAM; GLUTATHIONE; GOLD; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MERCURY; NITRIC OXIDE; PERVANADATE; PREDNISONE; RIBAVIRIN; SALICYLATE SODIUM; SANGUINARINE; TRANSCRIPTION FACTOR; UNINDEXED DRUG; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE; ZINC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; CANCER; CONTROLLED STUDY; DRUG TARGETING; GENE TARGETING; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 85047699198     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402482     Document Type: Review

References (283)

1. Cell stress genes and neuronal protection
2. NF-kB as a primary regulator of the stress response
3. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism
4. A novel IκB protein, IκB-ζ, induced by proinflammatory stimuli, negatively regulates nuclear factor-κB in the nuclei
5. Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation
6. Regulation of DNA binding by Rel/NF-kB transcription factors: Structural views
7. Activators and target genes of Rel/NF-kappaB transcription factors
8. Is NF-kappaB the sensor of oxidative stress?
9. Staphylococcus aureus and derived exotoxins induce nuclear factor kappa B-like activity in murine bone marrow macrophages
10. HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes
11. Expression of influenza virus hemagglutinin activates transcription factor NF-kappa B
12. Activation of nuclear factor-kappaB in the rat brain after transient focal ischemia
13. Early activation of transcription factor NF-kappaB during ischemia in perfused rat heart
14. UV-induced transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and UV-induced secretion of an extracellular factor that induces HIV-1 transcription in non-irradiated cells
15. Superoxide mediates cigarette smoke-induced infiltration of neutrophils into the airways through nuclear factor-kappaB activation and IL-8 mRNA expression in guinea pigs in vivo
16. Activation of NF-kappa B in murine macrophages by taxol
17. Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: Suppression of NF-kappaB and neuroprotection by antioxidants
18. Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production
19. Insulin activates nuclear factor kappa B in mammalian cells through a Raf-1-mediated pathway
20. Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-kappaB p65) transcription factor: One mechanism for the renin angiotensin system positive feedback loop in hepatocytes
21. Activation of NF-kappa B and immunoglobulin expression in response to platelet-activating factor in a human B cell line
22. Platelet-activating factor (PAF) positively auto-regulates the expression of human PAF receptor transcript 1 (leukocyte-type) through NF-kappa B
23. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1
24. Oxidative stress induces NF-kappaB nuclear translocation without degradation of IkappaBalpha
25. IkappaBalpha degradation is not a requirement for the X-ray-induced activation of nuclear factor kappaB in normal rat astrocytes and human brain tumour cells
26. Site-specific tyrosine phosphorylation of IκBα negatively regulates its inducible phosphorylation and degradation
27. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha
28. Erythropoietin-mediated neuroprotection involves cross-talk between JAK2 and NF-kB signalling cascades
29. How NF-kappaB is activated: The role of the IkappaB kinase (IKK) complex
30. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene
31. IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis
32. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway
33. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase
34. Limb and skin abnormalities in mice lacking IKKalpha
35. Novel NEMO/IkappaB kinase and NF-kappa B target genes at the pre-B to immature B cell transition
36. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex
37. NEMO/IKK gamma-deficient mice model incontinentia pigmenti
38. IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases
39. IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex
40. NF-kappaB activation through IKK-i-dependent I-TRAF/TANK phosphorylation
41. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1
42. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB
43. IKK-1 and IKK-2: Cytokine-activated IkappaB kinases essential for NF-kappaB activation
44. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation
45. Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: Discrimination between free and NF-kappaB-bound substrate
46. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation
47. A dominant negative protein kinase C zeta subspecies blocks NF-kappaB activation
48. TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: Involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway
49. Protein kinase C-alpha is an upstream activator of the IkappaB kinase complex in the TPA signal transduction pathway to NF-kappaB in U20S cells
50. Bimp1, a MAGUK family member linking protein kinase C activation to Bc110-mediated NF-kappaB induction
51. Immunodeficiency in protein kinase cbeta-deficient mice
52. Protein kinase C-theta participates in NK-kappaB activation induced by CD3-CD28 costimulation through selective activation of IkappaB kinase beta
53. Complex formation and cooperation of protein kinase C theta and Akt1/protein kinase B alpha in the NF-kappa B transactivation cascade in Jurkat T cells
54. NF-kappa B activation in tumor necrosis factor alpha-stimulated neutrophils is mediated by protein kinase Cdelta. Correlation to nuclear Ikappa Balpha
55. Up-regulation of protein kinase C-epsilon promotes the expression of cytokine-inducible nitric oxide synthase in RAW 264.7 cells
56. Activation of NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells
57. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B
58. TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein NF-kappaB1 p105
59. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB kinase-beta
60. The essential role of MEKK3 in TNF-induced NF-kappaB activation
61. NAK is an IkappaB kinase-activating kinase
62. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase
63. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription
64. Phosphatidylinositol 3-kinase in interleukin 1 signaling. Physical interaction with the interleukin 1 receptor and requirement in NFkappaB and AP-1 activation
65. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase
66. Mixed-lineage kinase 3 delivers CD3/CD28-derived signals into the IkappaB kinase complex
67. Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates IkappaB kinases (IKK-alpha/beta) and IKK-beta is a developmentally regulated protein kinase
68. Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor beta (TGF-beta)-activated kinase (TAK1), a kinase mediator transduction
69. Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor beta (TGF-beta)-activated kinase (TAK1), a kinase mediator transduction
70. Kappa B site-dependent induction of gene expression by diverse inducers of nuclear factor kappa B requires Raf-1
71. Activation of NF-kappa B by oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade
72. Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1
73. Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement
74. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300
75. The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism
76. Effects of antisense IRAK-2 oligonucleotides on PG12 release induced by IL-1 and TNF
77. Transactivation by the p65 subunit of NF-kappaB in response to interleukin-1 (IL-1) involves MyD88, IL-1 receptor-associated kinase 1, TRAF-6, and Rac1
78. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family
79. Protein tyrosine kinase p561ck is required for ceramide-induced by not TNF-induced cellular responses: Effect on activation of NF-kB, AP-1, JNK and apoptosis
80. Differential requirement for p561 ck in HIV-TAT vs. TNF-induced cellular responses: Effects on NF-kB, AP-1, JNK and apoptosis
81. Vanadate induction of NF-kappaB involves IkappaB kinase beta and SAPK/ERK kinase 1 in macrophages
82. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses
83. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells
84. B cells from p50/NF-kappa B knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching
85. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death
86. NF-kappa B RelA-deficient lymphocytes: Normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses
87. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression
88. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis
89. The regulation and roles of Rel/NF-kappa B transcription factors during lymphocyte activation
90. Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor
91. The Rel subunit of NF-kappaB-like transcription factors is a positive and negative regulator of macrophage gene expression: Distinct roles for Rel in different macrophage populations
92. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel
93. Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses
94. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture
95. Genetic approaches in mice to understand Rel/NF-kappaB and IkappaB function: Transgenics and knockouts
96. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice
97. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice
98. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis
99. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice
100. The NF-kappaB transcription factor in oncogenesis
101. Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target
102. The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma
103. P53, apoptosis and human cancers
104. Suppression of TNF-alpha-induced apoptosis by NF-kappaB
105. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates
106. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth
107. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB
108. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis
109. Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents
110. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2: In vitro antiproliferative effects of a COX-2 inhibitor
111. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors
112. The possible role of TNF-alpha and IL-2 in inducing tumor-associated metabolic alterations
113. Significant correlation between expression of interleukin-1 alpha and liver metastasis in gastric carcinoma
114. Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer
115. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells
116. Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis
117. Chemokines: Not just leukocyte chemoattractants in the promotion of cancer
118. Epithelial cancer cell migration: A role for chemokine receptors?
119. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity
120. Vascular endothelial growth factor (VEGF) and its role in neoplastic processes
121. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer
122. Effects of roxithromycin on tumor necrosis factor-alpha-induced vascular endothelial growth factor expression in human periodontal ligament cells in culture
123. Genomic organization of human and mouse genes for vascular endothelial growth factor C
124. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages
125. Regulation of tumor necrosis factor alpha transcription in macrophages: Involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B
126. NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene
127. 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter
128. An NF kappa B-like factor is essential but not sufficient for cytokine induction of endothelial leukocyte adhesion molecule 1 (ELAM-1) gene transcription
129. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1)
130. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues
131. Diagnostic and therapeutic applications of angiogenesis research
132. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death
133. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB
134. Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1
135. Efficient adenoviral transfer of NF-kappaB inhibitor sensitizes melanoma to tumor necrosis factor-mediated apoptosis
136. Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells
137. Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IkappaBalpha overexpression
138. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer
139. TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: Transcriptional activation of I kappa B alpha
140. Role of the Rel-family of transcription factors in the regulation of c-myc gene transcription and apoptosis of WEHI 231 murine B-cells
141. Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-kappaB
142. Survival-independent function of NF-kappaB/Rel during late stages of thymocyte differentiation
143. NF-kappaB activation is a critical regulator of human granulocyte apoptosis in vitro
144. Superoxide attenuates macrophage apoptosis by NF-kappa B and AP-1 activation that promotes cyclooxygenase-2 expression
145. The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation
146. Nerve growth factor-dependent activation of NF-kappaB contributes to survival of sympathetic neurons
147. Nuclear factor-kappa B regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells
148. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro
149. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-kappaB
150. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1
151. Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum
152. NF-kappaB is activated and promotes cell death in focal cerebral ischemia
153. Nitric oxide inhibits stress-induced endothelial cell apoptosis
154. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment
155. Role of NF-kappaB in the apoptotic-resistant phenotype of keratinocytes
156. Cytokine induced expression of porcine inhibitor of apoptosis protein (iap) family member is regulated by NF-kappa B
157. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1
158. NF-kappaB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition
159. C-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition
160. P53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300
161. NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2
162. Enhanced I kappa B alpha degradation is responsible for constitutive NF-kappa B activity in mature murine B-cell lines
163. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells
164. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells
165. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
166. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB
167. Cellular proliferation and activation of NF kappa B are induced by autocrine production of tumor necrosis factor alpha in the human T lymphoma line HuT 78
168. Expression of human inducible nitric oxide synthase gene in T-cell lines infected with human T-cell leukemia virus type-I and primary adult T-cell leukemia cells
169. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells
170. Rapid DNA binding by nuclear factor kappa B in hepatocytes at the start of liver regeneration
171. NFkappaB prevents apoptosis and liver dysfunction during liver regeneration
172. Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells
173. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression
174. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA
175. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
176. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells in inhibited by ibuprofen
177. An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells
178. Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells
179. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines
180. Down-regulation of NF-kappaB activity and NF-kappaB p65 subunit expression by ras and polyoma middle T oncogenes in human colonic Caco-2 cells
181. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2
182. The NF-kappa B transcription factor and cancer: High expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines
183. IkappaBalpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death
184. Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma
185. Enhanced radiosensitivity by inhibition of nuclear factor kappa B activation in human malignant glioma cells
186. NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells
187. Aberrant rel/nfkb genes and activity in human cancer
188. Chromosomal localization of genes encoding the transcription factors, c-rel, NF-kappa Bp50, NF-kappa Bp65, and lyt-10 by fluorescence in situ hybridization
189. PRAD1/cyclin D1 proto-oncogene: Genomic organization, 5′ DNA sequence, and sequence of a tumor-specific rearrangement breakpoint
190. Identification of a tumor-associated mutant form of the NF-kappaB ReIA gene with reduced DNA-binding and transactivating activities
191. Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract
192. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lyphoma
193. Chromosomal and gene amplification in diffuse large B-cell lymphoma
194. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene
195. Alterations at the rel locus in human lymphoma
196. Related subunits of NF-kappa B map to two distinct loci associated with translocations in leukemia, NFKB1 and NFKB2
197. Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105
198. Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies
199. Heterogeneous chromosomal aberrations generate 3′ truncations of the NFKB2/lyt-10 gene in lymphoid malignancies
200. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50
201. Molecular analysis of cutaneous B- and T-cell lymphomas
202. Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells
203. Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells
204. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha
205. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells
206. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway
207. Local administration of transcription factor decoy oligonucleotides to nuclear factor-kappaB prevents carrageenin-induced inflammation in rat hind paw
208. The guanylate cyclase-coupled natriuretic peptide receptor: A new target for prevention of cold ischemia-reperfusion damage of the rat liver
209. Interleukin-4 down-regulates both forms of tumor necrosis factor receptor and receptor-mediated apoptosis, NF-kappaB, AP-1, and c-Jun N-terminal kinase. Comparison with interleukin-13
210. Inhibition of NF-kappa B binding to DNA by chromium, cadmium, mercury, zinc, and arsenite in vitro: Evidence of a thiol mechanism
211. Inhibition of the DNA-binding activity of NF-kappa B by gold compounds in vitro
212. Inhibition of viral replication reverses respiratory syncytial virus-induced NF-kappaB activation and interleukin-8 gene expression in A549 cells
213. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells
214. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
215. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B
216. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun
217. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB
218. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B
219. Inhibition of NF-kappa B activation in vitro and in vivo: Role of 26S proteasome
220. Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors
221. Lactacystin, proteasome function, and cell fate
222. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition
223. Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase
224. Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B
225. Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-kappa B activation by diverse agents
226. Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors
227. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB
228. IL-13 suppresses TNF-induced activation of nuclear factor-kappa B, activation protein-1, and apoptosis
229. Protein-tyrosine phosphatase inhibitors block tumor necrosis factor-dependent activation of the nuclear transcription factor NF-kappa B
230. The effect of sodium salicylate and aspirin on NF-kappa B
231. Inhibition of NF-kappa B by sodium salicylate and aspirin
232. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells
233. NO inhibits cytokine-induced iNOS expression and NF-kappaB activation by interfering with phosphorylation and degradation of IkappaB-alpha
234. Inhibition of NF-kappaB DNA binding by nitric oxide
235. Assessing induction of I kappa B by nitric oxide
236. Inhibition of nuclear factor kappa B by prostaglandin A1: An effect associated with heat shock transcription factor activation
237. Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-kappaB activation, IkappaBalpha phosphorylation, and degradation
238. The yopJ locus is required for Yersinia-mediated inhibition of NF-kappaB activation and cytokine expression: YopJ contains a eukaryotic SH2-like domain that is essential for its repressive activity
239. IkappaB kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal
240. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex
241. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
242. Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis
243. IL-10 down-regulates human microglial IL-8 by inhibition of NF-kappaB activation
244. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13
245. Is NF-kappaB the sensor of oxidative stress?
246. Activators and target genes of Rel/NF-kappaB transcription factors
247. Structure, regulation and function of NF-kappa B
248. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells
249. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane)
250. Glutathione downregulates the phosphorylation of I kappa B: Autoloop regulation of the NF-kappa B-mediated expression of NF-kappa B subunits by TNF-alpha in mouse vascular endothelial cells
251. Antioxidants inhibit stimulation of HIV transcription
252. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence
253. Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: Prevention by calphostin C
254. An allosteric drug, o, o'-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 Tat and NF-kappa B
255. Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs
256. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells
257. Signal-induced degradation of I(kappa)B(alpha): Association with NF-kappaB and the PEST sequence in I(kappa)B(alpha) are not required
258. TAT fusion proteins containing tyrosine 42-deleted IkappaBalpha arrest osteoclastogenesis
259. Duration of nuclear NF-kappaB action regulated by reversible acetylation
260. Inhibition of the RelA(p65) NF-kappaB subunit by Egr-1
261. Involvement of Egr-1/RelA synergy in distinguishing T cell activation from tumor necrosis factor-alpha-induced NF-kappa B1 transcription
262. Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor
263. Inactivation of the inhibitory kappaB protein kinase/nuclear factor kappaB pathway by Par-4 expression potentiates tumor necrosis factor alpha-induced apoptosis
264. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression
265. Pro-apoptotic action of PAR-4 involves inhibition of NF-kappaB activity and suppression of BCL-2 expression
266. E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways
267. Transcriptional cross talk between NF-kappaB and p53
268. P300/CBP-dependent and - Independent transcriptional interference between NF-kappaB RelA and p53
269. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras
270. Association of Cdk2/cyclin E and NF-kappa B complexes at G1/S phase
271. Role of NF-kappaB in p53-mediated programmed cell death
272. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways
273. TRAF6 is a signal transducer for interleukin-1
274. I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction
275. Tumor necrosis factor (TNF)-mediated kinase cascades: Bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2
276. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B
277. NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176
278. Identification and characterization of an IkappaB kinase
279. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK
280. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules
281. A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways
282. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B
283. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis